A meta-analysis examined the efficacy and safety of transcatheter aortic valve replacement (TAVR) in 2773 patients with pure severe native aortic valve regurgitation based on 29 studies. The success rate of the device reached 87.5%, with perioperative all-cause mortality of 3.1% and cardiovascular mortality of 1.4%. The following complications occurred during surgery: stroke (0.7%), kidney injury (4.5%), major vascular complications (3.3%), major bleeding events (4.4%), and need for a new pacemaker (11.4%). At one year, overall mortality was 9.3%, cardiovascular mortality was 4.3%, and readmission for heart failure was 19.0%. The incidence of complications was influenced by geographic location, surgical risk of the patient, type of valve used, and procedure approach. The conclusion of the study confirms that TAVR represents a valuable therapeutic procedure for patients at high surgical risk, although the incidence of adverse events varies depending on several factors.